December 7th, 2010, a day that will live in infamy.
So this notion that somehow we are willing to compromise too much reminds me of the debate that we had during health care. This is the public option debate all over again. So I pass a signature piece of legislation where we finally get health care for all Americans, something that Democrats had been fighting for for a hundred years, but because there was a provision in there that they didn’t get that would have affected maybe a couple of million people, even though we got health insurance for 30 million people and the potential for lower premiums for 100 million people, that somehow that was a sign of weakness and compromise.
What goes around comes around.
The Ghosts Of Health Care Deals Past: Industry Negotiations Could Haunt WH In New GOP-Led Congress
Amanda Terkel and Ryan Grim, The Huffington Post
12-8-10 01:00 PM
WASHINGTON — The deals that the White House cut with major industries during the health care debate are threatening to come back to haunt the administration once Republicans take control of the House. One of the most closely-watched deals involved the White House working closely with a onetime foe, former GOP congressman Billy Tauzin, head of the drugmakers lobby. Now that the deal is done, Tauzin and the White House will find themselves once again on opposite sides. Tauzin, say people close to him, will be happy to talk.
Reps. Darrell Issa (R-Calif.) and Michael Burgess (R-Texas) will likely be the chairmen of the two committees that will have jurisdiction over any investigation into the health-care dealmaking. Both tell The Huffington Post they’re certain Tauzin is willing to chat.
“He’s a very transparent guy. He’s the kind of guy that’s happy to sit down and, you know, he doesn’t hide anything. If he made a deal as part of PhRMA with the White House, he’s going to tell you exactly what that deal was, who he made it with, what the terms were, et cetera,” said Burgess, the incoming chairman of the Energy and Commerce Oversight and Investigations Subcommittee.
1 comments
Author